Effects of 12  weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

ConclusionsThese studies demonstrated that bococizumab safely and effectively lowered LDL‐C in hypercholesterolemic subjects on high doses of statin.

Source: Cardiovascular Therapeutics - November 25, 2017 Category: Cardiology Authors: Sergio Fazio, David G. Robertson, Tenshang Joh, Hong Wan, Tom Riel, Philippe Forgues, Charles M. Baum, Pamela D. Garzone, Barry Gumbiner Tags: ORIGINAL RESEARCH ARTICLE Source Type: research